Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement

PURPOSE: Rearranged during transfection (RET) gene rearrangement is a well-known driver event in non–small cell lung cancer (NSCLC). Pralsetinib is a selective inhibitor of RET kinase and has shown efficacy in oncogenic RET-altered tumors. This study evaluated the efficacy and safety of expanded acc...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Youngkyung, Jung, Hyun Ae, Park, Sehhoon, Sun, Jong-Mu, Ahn, Jin Seok, Ahn, Myung-Ju, Park, Keunchil, Lee, Se-Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582535/
https://www.ncbi.nlm.nih.gov/pubmed/37218138
http://dx.doi.org/10.4143/crt.2023.403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582535/
https://www.ncbi.nlm.nih.gov/pubmed/37218138
http://dx.doi.org/10.4143/crt.2023.403

Ejemplares similares